Granted, revenue has still been higher over the past few years than it was before COVID-19, but the stock price is also down ...

Pfizer has a significant dividend payout, yielding over 6%. With its forward price-to-earnings (P/E) ratio of 9.6, it may ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Pfizer Inc. (NYSE:PFE) is one of the 8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA lowered the price target on ...

Pfizer has been struggling for several years. The company's pipeline could help it turn things around. It also has a solid dividend program and is attractively valued. 10 stocks we like better than ...

Although it's not generating tons of money from its COVID vaccine and pill anymore, the business is still doing well. There ...

Pfizer is a $145 billion pharmaceutical industry giant with a long history of success behind it. Wall Street bid the stock up during the COVID-19 pandemic, but now investors have soured on the shares.

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug ...

Pfizer has been struggling for several years. The company's pipeline could help it turn things around. It also has a solid dividend program and is attractively valued. Pfizer's revenue and earnings ...